ArticleNature immunology2019
The deubiquitinase Otub1 controls the activation of CD8
Open access · greenAbstract read
In one paragraph
Article in Nature immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 110 citations in OpenAlex.
- CD4Cell death & disease · 2022Trial
- METTL3‑mediated OTUB1 sustains PD‑L1 protein stability via deubiquitination and promotes immune evasion in oral squamous cell carcinoma.Molecular and cellular biochemistry · 2026Article
- OTUB1 Promotes HCC Progression by Regulating Glycolysis Through Deubiquitination of PKM2.Molecular carcinogenesis · 2026Article
- OTUB1 non-canonically inhibits TAB2 ubiquitination to govern microglia-mediated neuroinflammation.EMBO molecular medicine · 2026Article
- Targeting the OTU family: a core therapeutic strategy for reshaping the immunosuppressive microenvironment and reversing drug resistance in HCC by coordinating the autophagy-ferroptosis balance.Cell death discovery · 2026Review
- Post-Translational Regulation of CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Ubiquitin-centered post-translational modification crosstalk orchestrates tumor immunity and immunotherapy response.Experimental hematology & oncology · 2026Review
- Otubain deubiquitinases: Multi-layered regulators of cell fate, development, and stress responses across kingdoms.iScience · 2026Review
- OTU deubiquitinases in disease: roles and targeting.Trends in molecular medicine · 2026Review
- Combining Machine Learning, Single-Cell Sequencing Data, and Mendelian Randomization Studies to Explore the Correlation Between Ischemic Stroke and Inflammatory Pathway Genes.International journal of genomics · 2026Article
- The deubiquitinase USP17LA negatively regulates T-cell activation and attenuates anti-tumor immunity.EMBO reports · 2025Article
- Primary Cilia Formation Mediated by Hsa_Circ_0005185/OTUB1/RAB8A Complex Inhibits Prostate Cancer Progression by Suppressing Hedgehog Signaling Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Research Progress of NK Cells in Glioblastoma Treatment.OncoTargets and therapy · 2025Review
- Post-translational modification of NK cell receptors offers clues to antigenic specificity riddle.Frontiers in immunology · 2025Review
- Dissecting the dual role of OTU family proteins in tumor progression and immune escape.Frontiers in immunology · 2025Review
- Advances in the role of NK cells in MDS immune dysfunction and antitumor research.Frontiers in immunology · 2025Review
- LncRNAs in serum-derived extracellular vesicles are potential biomarker and correlated with immune infiltration in gastric cancer.Frontiers in immunology · 2025Article
- Review
- PILRB potentiates the PI3K/AKT signaling pathway and reprograms cholesterol metabolism to drive gastric tumorigenesis and metastasis.Cell death & disease · 2024Article
- Ubiquitin modification in the regulation of tumor immunotherapy resistance mechanisms and potential therapeutic targets.Experimental hematology & oncology · 2024Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 2 institutions in 2 countries.
Xiaofei ZhouDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jiayi YuDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xuhong ChengDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Baoyu ZhaoDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.
Ganiraju C ManyamDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6006-8961
Li ZhangDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kimberly SchlunsDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pingwei LiDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX, USA.ORCID http://orcid.org/0000-0002-1815-3107
Jing WangDepartment of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shao-Cong SunDepartment of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. ssun@mdanderson.org.ORCID http://orcid.org/0000-0001-7353-9400
The University of Texas MD Anderson Cancer Center · USTexas A&M University · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTpI2 Kinase in Macrophage Activation by MicrobesR01AI057555 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SUN, SHAO-CONG · 2004 to 2021
$6.7MMolecular Studies of Noncanonical NF-kb SignalingR01GM084459 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SUN, SHAO-CONG · 2008 to 2021
$4.4MSignaling Functions of the Tumor Suppressor CYLDR01AI064639 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SUN, SHAO-CONG · 2006 to 2014
$3.6MRegulation of T-cell function and autoimmune inflammation by deubiquitinases.R37AI064639 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SUN, SHAO-CONG · 2015 to 2021
$2.8MMolecular basis of viral DNA sensing through the cGAS-STING pathwayR01AI145287 · NIAID · TEXAS A&M AGRILIFE RESEARCH · PI Pingwei Li · 2019 to 2026
$2.5MGenerating a model system to elucidate in vivo functions of soluble IL-15 complexesR03AI121458 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SCHLUNS, KIMBERLY SUE · 2016 to 2017
$160kNCI NIH HHS P30 CA016672NIAID NIH HHS R01 AI057555NIAID NIH HHS R01 AI064639NIAID NIH HHS R01 AI145287NIAID NIH HHS R03 AI121458NIAID NIH HHS R37 AI064639NIGMS NIH HHS R01 GM084459
Abstract
CD8
Indexed as
AnimalsCD8-Positive T-LymphocytesCell DifferentiationCysteine EndopeptidasesDeubiquitinating EnzymesDisease Models, AnimalEnergy MetabolismHost-Pathogen InteractionsHumansInterleukin-15Killer Cells, NaturalLymphocyte ActivationMelanoma, ExperimentalMiceMice, TransgenicProtein BindingCysteine EndopeptidasesDeubiquitinating EnzymesInterleukin-15Otub1 protein, mouseProto-Oncogene Proteins c-aktReceptors, Interleukin-15
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.